April 2012 Drug Information Update - Pharmacy Benefits ...
April 2012 Drug Information Update - Pharmacy Benefits ...
April 2012 Drug Information Update - Pharmacy Benefits ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Gruenhaupt, Mark R.Ph. Argus Health Systems, Inc. c2005 Available from: www.argushealth.com [cited March 15, <strong>2012</strong>].<br />
Gruenhaupt, Mark R.Ph. Argus Health Systems, Inc. c2005 Available from: www.argushealth.com [cited March 29, <strong>2012</strong>].<br />
New Indications (Existing <strong>Drug</strong>s)<br />
AVONEX® PEN<br />
February 28, <strong>2012</strong><br />
FDA Approves AVONEX® PEN and Dose Titration Regimen<br />
Dosing Enhancements May Improve Treatment Experience for Patients Receiving AVONEX®<br />
(interferon beta-1a) for Multiple Sclerosis<br />
Today Biogen Idec announced that the U.S. Food and <strong>Drug</strong> Administration (FDA) has approved two<br />
separate dosing innovations designed to improve the treatment experience for patients receiving once-aweek<br />
AVONEX for relapsing forms of multiple sclerosis (MS). AVONEX PEN, the first intramuscular<br />
(IM) autoinjector approved for MS, incorporates a smaller needle and easier administration to help<br />
patients reduce anxiety about AVONEX self-injection. A new dose titration regimen, which gradually<br />
escalates the dose of AVONEX at treatment initiation, reduces the incidence and severity of flu-like<br />
symptoms that can occur at the beginning of therapy.<br />
Article link: http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1666473<br />
Source website: http://www.biogenidec.com/<br />
ANGELIQ® (Drospirenone and Estradiol) Tablets<br />
February 29, <strong>2012</strong><br />
U.S. FDA Approves Lower Dose Formulation of ANGELIQ® (Drospirenone and Estradiol) Tablets<br />
Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and <strong>Drug</strong> Administration<br />
(FDA) has approved a lower dose formulation of ANGELIQ® (drospirenone and estradiol) tablets to treat<br />
moderate to severe vasomotor symptoms due to menopause in women who have a uterus. The new<br />
formulation contains 0.25 mg drospirenone (drsp)/0.5 mg estradiol (E2) and will be available in the U.S.<br />
by prescription shortly.<br />
Article link: http://www.prnewswire.com/news-releases/us-fda-approves-lower-dose-formulationofangeliq-drospirenone-and-estradiol-tablets-140935233.html<br />
Source website: http://www.prnewswire.com/<br />
NATAZIA<br />
March 15, <strong>2012</strong><br />
U.S. FDA approves Natazia as the first combined oral contraceptive to treat heavy menstrual<br />
bleeding (HMB)<br />
The U.S. Food and <strong>Drug</strong> Administration (FDA) has approved a new indication for Natazia (estradiol<br />
valerate and dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by<br />
any diagnosed conditions of the uterus (womb), in women who choose to use a combined oral<br />
contraceptive for contraception.<br />
Article link: http://press.bayerhealthcare.com/en/press/news-details-page.php/14519/<strong>2012</strong>-0117<br />
Source website: http://www.bayerhealthcare.com/scripts/pages/en/index.php<br />
INTELENCE®<br />
March 27, <strong>2012</strong><br />
FDA Approves INTELENCE (etravirine) Tablets for Treatment-Experienced Pediatric Patients with<br />
HIV-1, Following Priority Review<br />
Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and <strong>Drug</strong><br />
Administration (FDA) has approved INTELENCE® (etravirine) to be administered in combination with<br />
other antiretroviral (ARV) medications for treatment of human immunodeficiency virus 1 (HIV-1) in<br />
treatment-experienced pediatric patients (6 years to